Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Catalysis . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN115057848B reveals a mild chiral synthesis route for high-purity axial chiral isopyrone-indole derivatives, offering significant supply chain and cost advantages for pharmaceutical manufacturing.
Patent CN118878543A reveals high-purity axial chiral synthesis. Delivers significant cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Novel chiral phosphoric acid catalyzed synthesis offers high optical purity and mild conditions for scalable pharmaceutical intermediate manufacturing and supply chain optimization.
Novel synthesis of axial chiral cyclopentenyl indole-naphthyl compounds via chiral phosphoric acid. High enantioselectivity and cytotoxic activity for pharmaceutical applications.
Patent CN113735867B introduces mild room temperature synthesis of chiral indolo-oxa compounds with high yield and enantioselectivity offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing
Patent CN114057717B introduces a novel quinoline-substituted bisoxazoline ligand achieving high enantioselectivity in asymmetric catalysis with mild industrial-scale synthesis conditions.
Novel chiral indolinopyrrole synthesis via phosphoric acid catalysis achieves high enantioselectivity and scalability, enabling cost-effective API intermediate production for oncology therapeutics.
Patent CN110452150B enables one-step synthesis of axial chiral indole-naphthalene compounds under mild conditions with high optical purity, offering significant cost reduction and reliable supply for pharmaceutical catalysis applications.
Breakthrough chiral phosphoric acid catalyst with spiro-bis-dihydrobenzothiole skeleton enables high-enantioselectivity asymmetric synthesis for pharmaceutical intermediates, offering reliable supply chain and cost reduction.
Novel chiral phosphoric acid-catalyzed synthesis achieves high enantioselectivity and yield for N-N axis pyrrole derivatives, enabling cost-effective pharmaceutical production with enhanced supply chain reliability.
Patent CN118666838B enables high-purity chiral intermediates through copper-catalyzed asymmetric synthesis, offering streamlined manufacturing and enhanced supply chain reliability for pharmaceutical applications.
Patent CN114478245A enables high-purity chiral intermediates with streamlined manufacturing and enhanced supply chain resilience for pharmaceutical applications.
Patent CN119060057B introduces a mild chiral phosphoric acid-catalyzed synthesis of indolocyclopentanes with high yield and selectivity, enabling scalable production and significant cost savings for pharmaceutical intermediates.
Breakthrough chiral indoxazinone synthesis with high enantioselectivity enables cost-effective manufacturing and reliable supply chain for oncology drug development.
Innovative chiral phosphoric acid catalyzed process delivers high enantioselectivity and yield for pharmaceutical intermediates ensuring scalable cost-effective production with stringent purity standards
Novel axial chiral naphthalene-pyrrole phosphine catalyst enables efficient asymmetric synthesis with simplified process flow and enhanced supply chain reliability for pharmaceutical intermediates.
This patent introduces a novel axial chiral naphthalene-pyrrole phosphine catalyst with mild reaction conditions and high enantioselectivity, enabling cost-effective production of chiral intermediates for pharmaceutical applications.
Novel chiral pyrrole synthesis method enables high-yield production with exceptional enantioselectivity, enhancing pharmaceutical supply chain reliability and cost efficiency.
Patent CN116199614B enables high-yield synthesis of chiral catalysts with up to 98% ee, offering cost-effective and scalable production for pharmaceutical intermediates.
Patent CN119060057B introduces a mild chiral phosphoric acid catalyzed route achieving high stereoselectivity and yield for indolocyclopentanes compounds with significant cost reduction potential in pharmaceutical manufacturing.